Education
About Us
Working with TipRanks
Follow Us
Immucell Corp. (ICCC)
NASDAQ:ICCC
Top Page
Immucell
(NASDAQ:ICCC)
61Neutral
Immucell (ICCC) vs. S&P 500 (SPY)
Market Cap
$47.63M
Dividend YieldN/A
Average Volume (3M)30.49K
Price to Earnings (P/E)―
Beta (1Y)>-0.01
Revenue Growth28.29%
EPS Growth87.42%
CountryUS
Employees69
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)0.16
Shares Outstanding9,037,397
10 Day Avg. Volume22,094
30 Day Avg. Volume30,493
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio0.04
Enterprise Value/Market Cap30.54
Enterprise Value/Revenue0.18
Enterprise Value/Gross Profit0.43
Enterprise Value/Ebitda-2.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Immucell Business Overview & Revenue Model
Company DescriptionImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
How the Company Makes MoneyImmuCell primarily generates revenue through the sale of its proprietary product, First Defense, which is marketed to dairy and beef producers. The company's revenue model is based on direct sales and distribution partnerships that expand its market reach. ImmuCell also engages in research and development to innovate new products and improve existing ones, potentially creating additional revenue streams through expanded product offerings. Key factors contributing to earnings include market demand for effective animal health products, successful distribution partnerships, and maintaining a strong reputation in the industry for efficacy and reliability.
Immucell Financial Statement Overview
Summary
ImmuCell exhibits strong revenue growth and a solid equity foundation, yet struggles with profitability and free cash flow sustainability. Positive trends in operating cash flow are encouraging, but profitability issues must be addressed.Income Statement
The company has demonstrated significant revenue growth, especially noted in the TTM period with a substantial increase in total revenue. However, profitability margins such as EBIT and net profit margins have been negative in recent annual reports, indicating ongoing challenges in achieving operational profitability.60
Neutral
Balance Sheet
The balance sheet shows a solid equity position with relatively moderate leverage, as indicated by a reasonable debt-to-equity ratio. The equity ratio is healthy, reflecting the company's ability to finance its operations through shareholder equity rather than excessive debt.70
Positive
Cash Flow
The company is generating a positive operating cash flow, especially in the TTM period, which indicates improvement in operational cash generation. However, past periods show negative free cash flow, which raises concerns about the company's ability to sustain capital expenditures and finance operations without external funding.65
Positive
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 8.09B | 26.49M | 17.47M | 18.57M | 19.24M | 15.34M | Gross Profit |
| 3.36B | 7.94M | 4.40M | 7.65M | 8.66M | 6.86M | EBIT |
| 541.97M | -1.64M | -5.75M | -2.30M | -2.20M | -1.38M | EBITDA |
| 543.31M | 1.04M | -2.50M | 349.99K | 2.72M | 1.65M | Net Income Common Stockholders |
| 1.45B | -2.16M | -5.77M | -2.49M | -78.00K | -1.02M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 4.60B | 3.76M | 978.74K | 5.79M | 10.19M | 7.95M | Total Assets |
| 45.62B | 45.10M | 43.81M | 44.86M | 44.47M | 40.35M | Total Debt |
| 6.01B | 15.10M | 16.69M | 12.48M | 10.27M | 10.73M | Net Debt |
| 1.41B | 11.34M | 15.71M | 6.69M | 89.03K | 2.79M | Total Liabilities |
| 12.76B | 17.58M | 18.82M | 14.48M | 11.89M | 12.08M | Stockholders Equity |
| 28.99B | 27.52M | 24.99M | 30.38M | 32.58M | 28.27M |
| Cash Flow | Free Cash Flow | ||||
| 1.24B | -107.82K | -6.57M | -5.52M | -1.65M | -2.76M | Operating Cash Flow |
| 1.57B | 357.90K | -4.67M | -1.54M | 954.17K | 1.32M | Investing Cash Flow |
| -329.44M | -461.23K | -1.89M | -3.96M | -1.60M | -2.57M | Financing Cash Flow |
| -400.40M | 2.88M | 1.75M | 1.11M | 3.88M | 1.91M |
Immucell Technical Analysis
Positive
5.27
Price Trends
5.15
Positive
5.16
Positive
4.49
Positive
Market Momentum
-0.03
Positive
51.59
Neutral
51.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICCC, the sentiment is Positive. The current price of 5.27 is below the 20-day moving average (MA) of 5.29, above the 50-day MA of 5.15, and above the 200-day MA of 4.49, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 51.59 is Neutral, neither overbought nor oversold. The STOCH value of 51.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ICCC.
Immucell Risk Analysis
Immucell disclosed 9 risk factors in its most recent earnings report. Immucell reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immucell Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $47.63M | ― | -1.01% | ― | 28.29% | 87.42% | |
52 Neutral | $5.15B | 3.02 | -44.64% | 2.83% | 16.44% | -0.47% | |
50 Neutral | $57.47M | ― | -71.64% | ― | -98.90% | -177.17% | |
44 Neutral | $60.85M | ― | -229.30% | ― | -42.30% | -330.51% | |
41 Neutral | $53.52M | ― | -181.84% | ― | -32.11% | 88.12% | |
39 Underperform | $30.67M | ― | -51.22% | ― | -5.72% | 48.12% |
* Healthcare Sector Average
Performance Comparison
ICCC
Immucell
5.27
0.53
11.18%
IRD
Opus Genetics
1.02
-0.77
-43.02%
FBIO
Fortress Biotech
1.81
-0.14
-7.18%
MODD
Modular Medical
0.97
-0.74
-43.27%
BNR
Burning Rock Biotech
2.85
-4.93
-63.37%
RPTX
Repare Therapeutics
1.34
-2.14
-61.49%
Immucell Earnings Call Summary
Earnings Call Date:May 14, 2025
(Q1-2025)
| % Change Since: 7.33%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong sales growth, improved gross margins, and significant adjusted EBITDA performance, driven by increased production capacity and product line expansion. However, challenges remain with FDA licensing for Re-Tain and managing backlog, alongside potential sales variability due to seasonality.Q1-2025 Updates
Positive Updates
Record-Breaking Sales Growth
Product sales during the first quarter of 2025 increased by 11% or $810,000 over the first quarter of 2024, reaching a record $8.1 million. This surpassed the previous record set in the fourth quarter of 2024.
Gross Margin Improvement
The gross margin increased to 42% in Q1 2025, up from 37% in Q4 2024, indicating operational improvements and higher production efficiency.
Significant Adjusted EBITDA Growth
Adjusted EBITDA improved significantly to $2.3 million in Q1 2025, compared to $458,000 in Q1 2024.
Successful Production Capacity Expansion
ImmuCell's production capacity increased to over $30 million annually, supporting future growth and reducing backlog from $4.4 million to $3.4 million.
First Defense Product Line Expansion
Introduction of new product formats for First Defense, expanding its use and market appeal.
No Recent Contamination Events
No contamination events reported for over a year, indicating improved production processes.
Negative Updates
Continued Challenges with Re-Tain FDA Approval
Delays in FDA licensing for Re-Tain due to inspection issues at a contract manufacturer, affecting the timeline for full commercial sales.
Backlog Management
Although reduced, the backlog still stands at $3.4 million, indicating ongoing demand and supply chain challenges.
Dependency on High Seasonal Sales
Q1 sales benefited from seasonal high demand, suggesting potential variability in future quarters.
Company Guidance
During the recent ImmuCell Corporation conference call, the company provided several key financial metrics and insights for the first quarter of fiscal year 2025. ImmuCell reported a record quarterly product sales revenue of $8.1 million, marking an 11% increase from the same period in 2024. The company also achieved a gross margin of 42% for the quarter, up from 37% in the fourth quarter of 2024, although they aim to reach at least 45%. Adjusted EBITDA showed significant improvement, with $2.3 million for the first quarter, compared to just $458,000 in the first quarter of 2024. The company's cash balance increased to $4.6 million as of March 31, 2025. ImmuCell reduced its order backlog from $4.4 million at the end of 2024 to $4 million by the end of the first quarter of 2025, with further reductions to $3.4 million by early May 2025. The company completed investments to expand production capacity to over $30 million annually, which contributed to their recent growth and financial recovery.Immucell Corporate Events
Executive/Board Changes
ImmuCell Appoints Timothy Fiori as New CFO
Positive
Apr 7, 2025
On April 7, 2025, ImmuCell Corporation announced the appointment of Timothy C. Fiori as its new Chief Financial Officer. Mr. Fiori brings 24 years of experience from Idexx Laboratories, where he held various financial and commercial roles. His appointment is seen as a strategic move to enhance ImmuCell’s growth, with expectations for him to improve financial systems and find efficiencies across the business.
Spark’s Take on ICCC Stock
According to Spark, TipRanks’ AI Analyst, ICCC is a Neutral.
Immucell Corporation shows some positive signs of recovery in its earnings call, with significant sales growth and improved margins. However, its financial performance remains challenged by operational losses and cash flow issues. Technical indicators show stability, but valuation metrics highlight profitability struggles. The company’s strategic initiatives offer potential, but risks remain from production challenges and regulatory delays.
To see Spark’s full report on ICCC stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.